RESULTS:
We included one randomized controlled trial and 21 observational studies. In total, there were 13,256 catheter insertions, including 4213 in patients with severe coagulopathy. Before 3150 central venous catheter placements, coagulopathy was not corrected. The bleeding incidence varied from 0 to 32%. The severity of coagulopathy did not predict the risk of bleeding. No study demonstrated a beneficial effect from the prophylactic administration of platelets or fresh-frozen plasma to prevent bleeding complications. Retrospective observational studies suggested that no preprocedural correction is required up to a platelet count of 20 3 10 9 /L and an international normalized ratio of 3.0.
CONCLUSION:
The incidence of major bleeding complications after central venous catheter placement is low, even in coagulopathic patients. Based on a systematic research of the literature, strong evidence supporting the correction of hemostatic defects before central venous catheter insertion is lacking. However, well-powered randomized controlled trials will be necessary to determine the minimal platelet count, the maximal international normalized ratio, and an activated partial thromboplastin time that is safe before central venous catheter insertion. C entral venous catheter (CVC) placement is a common procedure used to enable blood sampling, obtain central venous pressure measurements, and administer medication, chemotherapy, or total parental nutrition. [1] [2] [3] [4] CVCs are frequently inserted into patients who are at risk for coagulation disorders, including thrombocytopenia and prolonged bleeding (prothrombin time [PT] ). 5 Prophylactic correction of coagulopathy before CVC placement is associated with the prevention of bleeding complications. However, the use of platelet transfusion for patients with thrombocytopenia and of fresh-frozen plasma (FFP) in those with prolonged PT is potentially harmful. Transfusion products are associated with transfusion-related acute lung injury, transfusion-associated cardiac overload, allergic reactions, alloimmunization, and transfusion-related infections. [6] [7] [8] [9] [10] [11] [12] [13] Conclusive evidence of optimal platelet count and PT before CVC placement is lacking. 14 However, current national and international guidelines support the correction of thrombocytopenia up to a platelet count of 50 3 10 9 /L and an international normalized ratio (INR) 1.5 or greater before (CVC) placement. [15] [16] [17] The aim of this systematic review is to provide an overview of the current evidence on risk factors and incidence of bleeding complications after CVC placement in patients with severe coagulopathy.
MATERIALS AND METHODS

Literature search
The MEDLINE data was searched from January 1, 1980, through November 1, 2015, by using the following medical subject heading (MeSH) terms: complications, blood transfusion, blood plasma, fresh frozen plasma, platelets, central venous catheterization, central line, coagulopathy, and thrombocytopenia. The following text words were used: CVL (central venous line) and CVC. To identify observational studies, the MeSH terms case-control study and retrospective study were added. The Cochrane Library (2013), which contains the CENTRAL Database of Controlled Trials, the Database of Abstracts of Review Effectiveness, and the Cochrane Database of Systematic Reviews, also was searched.
In addition, we used the related articles feature of PubMed, which identifies related articles by using a hierarchical search engine that is not solely based on MeSH headings. This search was completed with articles selected by two of the authors (A.P.J.V. and B.V.). Although the search was also carried out for language citations not written in English, the resulting article review involved English-language publications only. The search strategy is detailed in Appendix 1.
Abstract review
After all citations based on our search strategy were identified, two of the authors (A.P.J.V. and B.B.) independently reviewed each abstract to assess its eligibility. Eligible studies were those that reported on CVC placement in patients with severe coagulopathy. To be included, studies had to report bleeding complications for a (sub)group of participants with at least one of the following characteristics: a reduced platelet count (50 3 10 9 /L) and an elevated INR (1.5) or a partial thromboplastin time (PTT) (45 seconds) before CVC placement. Articles were excluded if they were: 1) case reports, 2) had no full text available, 3) were not available in English, and 4) had Level 5 evidence according to the Oxford Centre for Evidence-based Medicine.
If an abstract was deemed eligible, then E.K.v.d.W. and A.P.J.V. independently reviewed the respective article, if available, to confirm that it met the inclusion criteria. The two reviewers either had to reach a consensus or use a fourth reviewer (J.M.B.) to resolve any discrepancies.
Data extraction
Data from the studies to describe study methods, study location, years of data collection, patient inclusion and exclusion criteria, patient characteristics, study findings, laboratory values, and transfusion policy were extracted using a predefined data-collection form. When available, we abstracted data on patients with and without correction of coagulopathy before CVC placement. Bleeding complications were categorized as major or minor bleeding, as reported by the article. Definitions of bleeding complications for each study were extracted and reported.
Article review process
One author reviewed each article (E.K.v.d.W.). Author and journal names were disclosed to the reviewer. All data were extracted by E.K.v.d.W. and were verified for accuracy by the second reviewer (A.P.J.V.).
Quantitative pooling and presentation of findings
Because of qualitative heterogeneity of the studies and patient heterogeneity, the results were not mathematically pooled. Since most studies lacked a comparison group, it was not possible to calculate risk differences. We assessed the risk of bias using the following criteria: 1) whether patient selection occurred randomly or consecutively versus other, 2) whether investigators excluded non-prespecified patient groups, 3) explicitness of bleeding criteria, 4) correction of hemostasis by transfusion products standardized versus left to the discretion of the physician, 5) a protocol for CVC placement, and 6) primary data collection versus data chart reports. The results of the assessment are provided in Appendix 2.
RESULTS
The searches of MEDLINE and the Cochrane Library yielded 302 unique articles for screening, and four additional records were identified through other sources based on the title. Subsequently, 79 articles were screened at the abstract level using the inclusion and exclusion criteria. Thirty-one full-text articles were assessed for eligibility. In total, 22 articles, including 21 observational studies and one randomized controlled trial, were reviewed for bleeding complications. All studies reported on patients who had a platelet count below 50 3 10 9 /L, an INR greater than 1.5, and/or an activated PTT (aPTT) greater than 45 seconds.
Included studies
In the 22 included studies, a total of 13,256 catheter placements were performed, of which 4213 took place in patients with severe coagulopathy. Before the placement of 1083 CVCs, coagulopathy was corrected with blood donor platelets or plasma. In 3150 coagulopathy was still present during cannulation. We retrieved only one randomized trial. This was an open-label, endpoint-blinded trial comparing prophylactic use of fresh-frozen plasma with no correction of an elevated INR in intensive care patients undergoing an invasive procedure. 18 We included 13 prospective cohort studies and eight retrospective series. In the prospective studies, coagulopathy was not corrected in six studies and was corrected in all patients in one study, at various fixed thresholds in two studies (Table 1) , [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] was at the physician's discretion in five studies. For the retrospective cohort studies, coagulopathy was corrected at a fixed threshold of 20 3 10 9 /L in one study, was corrected at the physician's discretion in six studies, and was not corrected in one study. Characteristics of studies, patients, procedures, and coagulopathies are displayed in Table 1 .
The primary focus of the articles included bleeding complications, infectious complications, mechanical complications, technical success rates, method of insertion, site of insertion, the benefit of FFP transfusion, and the benefit of platelet transfusion. Endpoints were technical insertion success rates or various catheter-related complications, such as mechanical complications, bleeding, thrombosis, and infection.
Study quality
The level of quality of the studies was low. In seven of eight studies that reported major bleeding events, patient and laboratory characteristics were incompletely reported. Data were retrospectively collected by patient charts in nine studies. In five studies, patients who received preprocedural transfusions were excluded. The only randomized controlled trial that was included lacked reliability, because it included only 81 instead of the intended 400 patients. 18 
Coagulopathy
The definition of coagulopathy and its concomitant laboratory thresholds varied across studies. The distribution of abnormal coagulation values and the preprocedural correction of coagulopathy are displayed in Table 1 . Thrombocytopenia contributed to the majority of coagulation disorders. Six studies combined the various coagulation test abnormalities into one group. [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] Abnormal coagulation parameters were combined in groups with different terms, such as "severe abnormalities," "high risk of bleeding," "coagulopathy," or "moderate-to-severe hemostatic disorders." Three studies did not report separate coagulation parameters and also did not specify the number of patients who had more than one abnormal laboratory value. To avoid counting patients who had multiple hemostatic effects more than once, only the largest group was used.
Bleeding complications
The definitions of both minor and major bleeding varied widely across studies (Table 2) . Major bleeding complications were categorized as reported by the article. We identified eight studies that reported a total of 13 major bleeding complications (Table 3) . 20, 21, 24, 26, 28, 30, 36, 38 Eight major bleeding complications were observed in patients with severe coagulopathy, and five were reported in patients with mild-to-absent coagulopathy. Only one study provided detailed values of classical coagulation parameters.
Overall bleeding prevalence in the included studies varied from 0 to 32%. Notably, in the study that reported a 32% bleeding prevalence in the presence of coagulopathy, the overall bleeding incidence was not different among the patients without coagulopathy (p 5 0.768). 42 
Platelet count
No randomized controlled trial evaluating the effect of prophylactic platelet transfusion was identified. Twenty studies reported patients or a subgroup of patients with platelet counts below 50 3 10 9 /L. These single-arm studies in patients with thrombocytopenia, without a comparison group, reported a bleeding incidence that varied from 0 to 32%.
Thrombocytopenia was not corrected before cannulation in seven studies. In this uncorrected group with platelet counts below 50 3 10 9 /L, no major bleeding events occurred. In three of these studies without prophylactic platelet transfusion, thrombocytopenia was identified as a risk factor for local hematoma and oozing. 23, 24, 41 One study reported no association between thrombocytopenia and minor bleeding complications. 38 In 11 studies, a small group of patients received platelet transfusion. The decision for prophylactic platelet transfusion was left to the discretion of the physician. No major hemorrhagic events occurred in the patients with platelet counts below 50 3 10 9 /L. Two studies identified thrombocytopenia as a risk factor for local hematoma and oozing. 28, 42 All of these hematomas were self-limiting, and oozing could be managed by prolonged manual compression or bandage changes in most cases. Mumtaz and colleagues reported that over-sewing of the catheter site was an effective solution in case of prolonged bleeding. 28 One study by Kander and coworkers revealed no association between thrombocytopenia and minor bleeding complications. 26 Zeidler and colleagues demonstrated no association between platelet count (down to a count of 20 3 10 9 /L) and bleeding risk. 42 Of note, all physicians were experienced, and CVC placement was ultrasound guided.
In three studies all patients with a low platelet count received prophylactic platelet concentrate, based on a threshold, varying from 10 to 50 3 10 9 /L. All patients had a platelet count of 30 3 10 9 /mL or less and received prophylactic platelet transfusion in one study. 33 Another observational study compared three groups of patients based on platelet counts of less than 50 3 10 9 /L (N 5 37), from 50 to 100 3 10 9 /L (N 5 35), and greater than 100 3 10 9 /L (N 5 33). There were no major bleeding complications. 35 Notably, patients in the first group received a transfusion of 1 unit of platelets during CVC placement. The use of FFP was left to the physicians' discretion. No bleeding occurred in patients without prophylactic plasma (0 of 73 patients), one case of bleeding occurred in a patient with an INR of 3.9 who had received plasma (1 of 27 patients), and no benefit of prophylactic plasma was observed (p 5 0.6).
International normalized ratio
Partial thromboplastin time
Four studies reported CVC placements in patients or a subgroup of patients with a PTT of 45 seconds or more in the absence of correction. No association between prolonged PTT and major or minor bleeding was observed.
Other risk factors
Several procedural factors were associated with bleeding complications. An analysis of the influence of catheter site produced conflicting results, which varied from no effect to favoring the internal jugular or subclavian site. 19, 23, 24, 42 More than one needle pass into the vein was associated with bleeding in three studies, 19, 33, 40 Other mechanical factors associated with bleeding complications included failed access at the initial site, failure to pass any guidewire, and documented arterial puncture. 24, 30 Several studies reported no association of mechanical factors with bleeding. No specific definition (no. not reported)
The overall occurrence of bleeding was 0.3% (95% CI, 0%-2%); no bleeding occurred in patients without prophylactic plasma, (n 5 0/73); one case of bleeding occurred in the group of patients that had received plasma (n 5 1/ 27); no benefit of prophylactic plasma was observed (p 5 0.6) DeLoughery 1996 21 No specific definition (N 5 2) (Table 3) Oozing of blood, manageable with dressing changes (N 5 10)
By combining coagulation test, a group at high risk for bleeding could be identified Della Vigna 2009 Bleeding that requires direct pressure for 10-20 min; 5 patients had bleeding from the skin, 2 small periosteal hematomas (N 5 7; 6.5%)
PLT count was the only risk factor statistically associated with minor bleeding; the PLT count associated with this risk in this series was <38,000/mL (in all but one patient, it was 25,000/mL) Fisher 1999 24 Any hemodynamically significant hemorrhage (N 5 1) ( Various patient characteristics were associated with hemorrhagic complications. One study reported more bleeding complications in medical patients compared with surgical or trauma patients. 21 The presence of ascites was also identified as an independent risk factor for postprocedural bleeding. 40 In another study, fibrinogen levels were significantly lower in the bleeding group (4.1 g/dL; range, 1.0-14.4 g/dL) compared with the nonbleeding group (4.8 g/dL; range, 0.7-14.7 g/dL). 42 
DISCUSSION
Our goal was to identify the incidence and risk factors of bleeding complications after central venous catheterization in patients with severe hemostatic defects. The 22 included studies indicated that major bleeding complications are rare in patients with thrombocytopenia and/or prolonged bleeding time. However, the exact values of platelet count, INR, and PTT in which central venous catheterization can safely be performed remain unclear. A major shortcoming of the current literature on bleeding complications after CVC placement in the presence of coagulopathy is study design. Except for one, all included studies had an observational cohort design. The rationale for correction of coagulopathy was often incompletely reported.
Furthermore, the definition of bleeding complications varied widely across studies. The reporting of minor bleeding complications varied from no reporting to the reporting of hematomas, prolonged oozing, and small interventions, such as the placement of a suture, bandage dressing, or prolonged manual compression. The lack of consistency in definitions of bleeding complications is a serious problem. A uniform definition should be used in studies that investigate bleeding complications. In addition, outcomes should be scored on clinically relevant bleeding, because the clinical relevance of a minor bleeding complication may be questionable.
Abnormal coagulation parameters are observed more frequently in patients who have bleeding complications compared with those without bleeding complications after CVC placement. However, the severity of coagulopathy does not correspond with the bleeding risk. In various invasive procedures, there is insufficient evidence that coagulation test results predict bleeding. 14, 44 DeLoughery and coworkers stated that a group at high risk for bleeding could be identified. Unfortunately, the predictive value of the combination of coagulation abnormalities could not be proven. Other authors found no difference in the incidence of hemorrhagic complications for independent coagulation variables alone. 21, 30 The association between severe thrombocytopenia and minor bleeding complications is consistent for the included studies: seven studies reported evidence supporting this result, whereas only two found no association. The correction of hemostatic defects before CVC placement remains a matter of debate. The introduction of ultrasound guidance for CVC placement led to a decrease in the number of puncture attempts and complication rates. [45] [46] [47] [48] [49] Current national and international guidelines are based on the landmark technique and subsequently still support correction of thrombocytopenia up to a platelet count of 50 3 10 9 /L and an INR of 1.5 or greater before CVC placement. [15] [16] [17] Various authors advise transfusing platelets below a platelet count of 20 3 10 9 / L. 19, 39, 42 However, there is no profound evidence to support this threshold. The minimum platelet count at which central cannulation can safely be performed without prophylactic platelet transfusion may be less than 20 3 10 9 /L. Several studies revealed no significant difference in the outcome of bleeding complications in patients who attained precatheter correction of hemostasis. 18, 28 Two studies reported no positive effect of prophylactic FFP administration on bleeding complications in patients with prolonged PT. 18, 35 In one observational cohort study, patients who received FFP had a higher baseline INR. 35 This may have reduced the positive effect of prophylactic FFP. That study had a high risk of selection bias. FFP transfusion was left to the discretion of the operator, and no clear rationale for FFP could be identified in a substantial amount of patients. The mere preprocedural measurement of PT was a risk factor for FFP transfusion. The other study was a moderate to high-quality, randomized controlled trial that lacked statistical power because of a low inclusion rate. 18 The prevalence of hematoma has also been associated with insertion technique. In an observational study, 1584 placements by the landmark method were compared with 2367 catheter placements after the introduction of ultrasound guidance. The incidence of hematoma decreased from 8.2% in the landmark group to 1.6% after the introduction of ultrasound guidance. 50 Our study included studies that used both insertion methods.
Our review comes with several limitations. The retrospective and/or observational nature of most of the studies we included is a disadvantage. Because of the observational design, patient selection may have occurred. In a study by Mey and colleagues, puncture teams in which both the sonographer and the puncturing physician were experienced produced more complications compared with teams in which only the sonographer was experienced. 27 This was explained as a result of bias, which made experienced physicians more likely to perform the procedure in clinical situations that made puncture difficult. Important gaps in methodological reporting and the acknowledgement of bias and confounders have been described previously in clinical platelet transfusion studies. 51 Therefore, the low occurrence of bleeding in severely coagulopathic patients may be confounded by more precocious measures before cannulation, such as placement by more experienced staff members or the selective use of ultrasound for high-risk patients. The positive effect of ultrasound guidance and the effect of experience with the procedure on complication rates have previously been demonstrated. 46, [52] [53] [54] Hence, it is suggested that the risk of bleeding after central venous catheterization is multifactorial and includes procedural, patient, and physician characteristics. The number of attempts, inadvertent arterial puncture, vein size, vein lesion, patient compliance, obesity, and hyperinflation have been associated with bleeding risk. 37, 55 Echo guidance can be used to identify the vessel or to advance the needle under real-time ultrasound guidance. 56 The use of real-time ultrasound and experience with the procedure reduce the complication rate. 46, 52, 54 Real-time ultrasound guidance was not yet available at the time of all studies we included, and this may have caused bias between studies. Therefore, it is difficult to assess the sole effect of coagulopathy in current observational cohort studies.
In conclusion, our systematic review of the published literature demonstrates that major bleeding after CVS placement is rare in patients with severe coagulopathy. The severity of coagulopathy does not correspond with the bleeding risk. Well-powered randomized controlled trials are necessary to determine the minimal platelet count and the maximal, safe INR and PTT values before CVC insertion. In these trials, the definition of bleeding complications should be uniform, the physicians involved should be experienced, and standard use of ultrasound should be compulsory.
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APPENDIX 1: SEARCH STRATEGY
We searched allowing any study design, except for case report. Controlled trials, retrospective or prospective cohort study, case-control study, casecontrol study, case series. Bleeding complications related to CVC placement had to be reported as an outcome. The subgroup of patients with coagulopathy should be defined, and the bleeding complications should be reported for this subgroup. We only included studies in adults. In order not to miss any relevant publication, no filter was used and pediatric records were excluded manually.
Patients must have received a central venous catheter. We performed four searches, with the search terms as described below. An initial search was performed on 01-01-2015, after which the selection of eligible articles took place. The search was repeated on 01-11-2015, to include recent articles. The first three searches were performed in MED-LINE using PUBMED with the search terms as described below. This resulted in a total of 338 hits, 302 after removal of duplicates. A search in the Cochrane library added 16 titles, of which 15 were unique. 34 pediatric studies were excluded. 3 studies were excluded for not being available in the English language. 3 studies were excluded for not being available in full-text. 83 abstract were checked for suitability using a predefined form. Of all the 83 articles that were screened on abstract level, we performed a "related articles" search. Relevant articles were checked for duplicates, after which four articles were identified for abstract review. Of the 83 abstract screened, 31 full-text articles were carefully read to obtain relevant information. A total of 22 articles were included in the current review.
The specific search terms were as follows:
